JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 85 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $46 | -99.9% | 25,000 | +25.0% | 0.00% | 0.0% |
| Q3 2022 | $47,000 | -23.0% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $61,000 | -55.1% | 20,000 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $136,000 | -18.6% | 20,000 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $167,000 | +125.7% | 20,000 | +100.0% | 0.00% | +200.0% |
| Q3 2021 | $74,000 | -71.0% | 10,000 | 0.0% | 0.00% | -80.0% |
| Q2 2021 | $255,000 | +147.6% | 10,000 | 0.0% | 0.01% | +150.0% |
| Q1 2021 | $103,000 | +47.1% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $70,000 | -14.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $82,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |